Eczema drug interaction study: will rocatinlimab change how other meds work?

NCT ID NCT05891119

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase study looked at how rocatinlimab, an experimental drug for eczema, affects the way the body processes several common medications (caffeine, metoprolol, midazolam, warfarin, omeprazole). 21 adults with moderate to severe eczema took these drugs with and without rocatinlimab to measure any changes. The goal was to gather safety and interaction data, not to treat the eczema itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rocatinlimab (AMG 451)
What this could lead to: If successful, this study could help doctors understand how rocatinlimab interacts with other medications, guiding safer use in future eczema treatments.
What could go wrong: This is a very early, small study (21 people) focused on drug interactions, not on treating eczema. It may not lead to any new treatment or change in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Accel Research Sites (ACR)

DeLand, Florida, 32720-3134, United States
Axis Clinicals, LCC

Dilworth, Minnesota, 56529, United States
DermDox Dermatology Centers, PC - Camp Hill

Camp Hill, Pennsylvania, 17011, United States
DermDox Dermatology Centers, PC - Sugarloaf

Nashville, Tennessee, 37203-1632, United States
Direct Helpers Research Center (DHRC)

Hialeah, Florida, 33012-3618, United States
Velocity Clinical Research -Spartanburg

Spartanburg, South Carolina, 29303-4225, United States
Velocity Clinical Research, North Hollywood

North Hollywood, California, 91606-1570, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.